A Single-arm Clinical Trial to Investigate COVID-19 Specific Vaccine and Heterologous Immunity in the Melbourne Infant Study of BCG for Allergy and Infection Reduction (COSI BAIR)
The COSI BAIR trial, sponsored by the Murdoch Childrens Research Institute, focuses on the effects of the COVID-19 vaccine on immunity in children aged 5 to 8 years. With a completion date of September 2022, the study aims to elucidate the specific and heterologous effects of COVID-19 vaccination, potentially influencing future pediatric vaccination strategies. The findings may enhance the understanding of vaccine responses in children, providing a competitive edge in the pediatric vaccine market, especially in the context of ongoing global vaccination efforts against COVID-19. Given the increasing focus on vaccine safety and efficacy in younger populations, the results could have significant implications for public health policies and vaccine development strategies.
Indication: COVID-19
Modality: protein therapy
Target: COVID-19 specific immunity and heterologous immunity mechanisms in children
Sponsor: Murdoch Childrens Research Institute
Source URL: ClinicalTrials.gov
Source updated: Feb 09, 2023
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: COVID-19 specific immunity and heterologous immunity mechanisms in children
View original source fields
Condition raw: COVID-19, Vaccine Reaction, Immunization; Infection
Condition normalized: COVID-19, Vaccine Reaction, Immunization; Infection
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: COVID-19 specific immunity and heterologous immunity mechanisms in children
Target normalized: COVID-19 specific immunity and heterologous immunity mechanisms in children